Glaukos Corporation (NYSE:GKOS) has been assigned a consensus rating of “Buy” from the nine ratings firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $45.00.

Several equities research analysts recently issued reports on GKOS shares. BMO Capital Markets reduced their price objective on shares of Glaukos from $45.00 to $40.00 and set an “outperform” rating for the company in a research note on Wednesday, November 8th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Glaukos in a research note on Tuesday, November 7th. Stephens reissued an “overweight” rating and set a $40.00 target price (down previously from $47.00) on shares of Glaukos in a research report on Monday, November 13th. Zacks Investment Research raised shares of Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, November 13th. Finally, BidaskClub lowered shares of Glaukos from a “buy” rating to a “hold” rating in a research report on Monday, September 18th.

In other news, CFO Joseph E. Gilliam bought 2,100 shares of the business’s stock in a transaction on Wednesday, November 22nd. The stock was purchased at an average price of $23.84 per share, with a total value of $50,064.00. Following the transaction, the chief financial officer now directly owns 102,100 shares in the company, valued at $2,434,064. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 16.40% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. increased its holdings in shares of Glaukos by 93.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 1,212 shares during the period. Valeo Financial Advisors LLC bought a new position in shares of Glaukos during the 3rd quarter worth about $111,000. BNP Paribas Arbitrage SA increased its holdings in shares of Glaukos by 740.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock worth $147,000 after purchasing an additional 3,118 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Glaukos during the 2nd quarter worth about $262,000. Finally, UBS Asset Management Americas Inc. bought a new position in shares of Glaukos during the 2nd quarter worth about $274,000. Institutional investors own 99.23% of the company’s stock.

Glaukos (NYSE:GKOS) traded up $0.20 during mid-day trading on Monday, hitting $26.25. 411,468 shares of the company traded hands, compared to its average volume of 475,717. Glaukos has a 1-year low of $23.08 and a 1-year high of $52.49. The firm has a market cap of $900.43, a price-to-earnings ratio of -656.09, a PEG ratio of 37.75 and a beta of 1.02.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.06. Glaukos had a negative net margin of 0.64% and a positive return on equity of 3.50%. The business had revenue of $40.41 million during the quarter, compared to analyst estimates of $38.69 million. During the same quarter in the previous year, the business earned $0.03 EPS. Glaukos’s quarterly revenue was up 36.6% compared to the same quarter last year. research analysts predict that Glaukos will post -0.01 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally published by Marea Informative and is the sole property of of Marea Informative. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.mareainformativa.com/2018/01/29/glaukos-corporation-gkos-given-average-recommendation-of-buy-by-brokerages-updated-updated-updated.html.

About Glaukos

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Analyst Recommendations for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.